News Quantified

CANF – can-fite biopharma ltd american depositary shares, each representing two (2) ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson [Yahoo! Finance]

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson

Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Can-Fite BioPharma (NYSE:CANF) had its price target lowered by analysts at D. Boral Capital from $11.00 to $4.00. They now have a "buy" rating on the stock.

Form 6-K Can-Fite BioPharma Ltd. For: Jan 27

Form 6-K Can-Fite BioPharma Ltd. For: Jan 20

Form 6-K Can-Fite BioPharma Ltd. For: Jan 16

Form 6-K Can-Fite BioPharma Ltd. For: Dec 23

Form 6-K Can-Fite BioPharma Ltd. For: Dec 16

Top News Gainers

11/29 Visiongain Report Claims There is Huge Potential Within the $39bn Dermatological Drugs Market 43.6%

12/26 Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing 30.5%

3/5 Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus 24.5%

9/10 Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays 23.2%

4/13 Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately 22.5%

4/2 Form 6-K/A Can-Fite BioPharma Ltd. For: Apr 02 17.2%

3/11 Form 6-K Can-Fite BioPharma Ltd. For: Mar 11 16.0%

1/3 New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss 12.8%

5/30 Form SC 13D Can-Fite BioPharma Ltd. Filed by: Capital Point Ltd. 9.4%

2/12 Form 6-K Can-Fite BioPharma Ltd. For: Feb 12 8.9%

Top News Decliners

5/20 Can-Fite BioPharma Announces $6 Million Registered Direct Offering -53.0%

10/17 Form 6-K Can-Fite BioPharma Ltd. For: Oct 17 -48.6%

2/10 Can-Fite BioPharma Announces Pricing of $5 Million Public Offering -43.4%

1/9 Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million -19.7%

3/13 Form 6-K Can-Fite BioPharma Ltd. For: Mar 13 -19.4%

10/31 Can-Fite up 36% premarket on advancement of Namodenoson [Seeking Alpha] -19.3%

8/1 Form 6-K Can-Fite BioPharma Ltd. For: Aug 01 -19.2%

4/7 Form 6-K Can-Fite BioPharma Ltd. For: Apr 07 -18.8%

2/27 Form 6-K Can-Fite BioPharma Ltd. For: Feb 27 -16.8%

3/23 Form 6-K Can-Fite BioPharma Ltd. For: Mar 23 -15.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day